Abstract
Cannabinoids have been used medicinally and recreationally for thousands of years
and their effects were proposed to occur mainly via activation of the G-protein-coupled
receptor
Cannabinoids have been used medicinally and recreationally for thousands of years
and their effects were proposed to occur mainly via activation of the G-protein-coupled
receptor
R. Mechoulam and Y. Gaoni, “Hashish. IV. The isolation and structure of cannabinolic cannabidiolic and cannabigerolic acids,” Tetrahedron, vol. 21, no. 5, pp. 1223–1229, 1965.
View at: Publisher Site | Google ScholarA. C. Howlett, “Pharmacology of cannabinoid receptors,” Annual Review of Pharmacology Toxicology, vol. 35, pp. 607–634, 1995.
View at: Google ScholarR. Mechoulam, E. Fride, and V. Di Marzo, “Endocannabinoids,” European Journal of Pharmacology, vol. 359, no. 1, pp. 1–18, 1998.
View at: Publisher Site | Google ScholarS. A. Cook, J. A. Lowe, and B. R. Martin, “CB1 receptor antagonist precipitates withdrawal in mice exposed to 9- tetrahydrocannabinol,” Journal of Pharmacology and Experimental Therapeutics, vol. 285, no. 3, pp. 1150–1156, 1998.
View at: Google ScholarT. Nadulski, F. Pragst, and G. Weinberg et al., “Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of thc verses standardized cannabis extract,” Therapeutic Drug Monitoring, vol. 27, no. 6, pp. 799–810, 2005.
View at: Publisher Site | Google ScholarR. G. Pertwee, “Pharmacology of cannabinoid CB1 and CB2 receptors,” Pharmacology and Therapeutic, vol. 74, pp. 129–180, 1997.
View at: Google ScholarB. R. Martin, D. R. Compton, and B. F. Thomas et al., “Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs,” Pharmacology Biochemistry and Behavior, vol. 40, no. 3, pp. 471–478, 1991.
View at: Publisher Site | Google ScholarW. A. Devane, A. Breuer, T. Sheskin, T. U. C. Jarbe, M. S. Eisen, and R. Mechoulam, “A novel probe for the cannabinoid receptor,” Journal of Medicinal Chemistry, vol. 35, no. 11, pp. 2065–2069, 1992.
View at: Google ScholarD. M. Lambert and C. J. Fowler, “The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications,” Journal of Medicinal Chemistry, vol. 48, no. 16, pp. 5059–5087, 2005.
View at: Publisher Site | Google ScholarK.-O. Jonsson, S. Vandevoorde, D. M. Lambert, G. Tiger, and C. J. Fowler, “Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide,” British Journal of Pharmacology, vol. 133, no. 8, pp. 1263–1275, 2001.
View at: Google ScholarA. C. Howlett, F. Barth, and T. I. Bonner et al., “International union of pharmacology. XXVII. Classification of cannabinoid receptors,” Pharmacological Reviews, vol. 54, no. 2, pp. 161–202, 2002.
View at: Publisher Site | Google ScholarJ. L. Wiley and B. R. Martin, “Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes,” Chemistry and Physics of Lipids, vol. 121, no. 1-2, pp. 57–63, 2002.
View at: Google ScholarD. Smart and J. C. Jerman, “Anandamide: an endogenous activator of the vanilloid receptor,” Trends in Pharmacological Sciences, vol. 21, no. 4, p. 134, 2000.
View at: Publisher Site | Google ScholarA. Calignano, R. G. La, and D. Piomelli, “Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide,” European Journal of Pharmacology, vol. 419, no. 2-3, pp. 191–198, 2001.
View at: Publisher Site | Google ScholarV. Di Marzo, C. S. Breivogel, and Q. Tao et al., “Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain,” Neurochemical Research, vol. 75, no. 6, pp. 2434–2444, 2000.
View at: Google ScholarC. S. Breivogel, G. Griffin, V. Di Marzo, B. R. Martin, R. K. Razdan, A. M. Zimmer, A. Zimmer, and B. R. Martin, “Evidence for a new G protein-coupled cannabinoid receptor in mouse brain,” Molecular Pharmacology, vol. 60, no. 1, pp. 155–163, 2001.
View at: Google ScholarE. B. Russo, A. Burnett, B. Hall, and K. K. Parker, “Agonistic properties of cannabidiol at 5-HT1a receptors,” Neurochemical Research, vol. 30, no. 8, pp. 1037–1043, 2005.
View at: Publisher Site | Google ScholarS. S. Davies, A. V. Pontsler, and G. K. Marathe et al., “Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor ligands and agonists,” Journal of Biological Chemistry, vol. 276, no. 19, pp. 16015–16023, 2001.
View at: Publisher Site | Google ScholarM. Gottlicher, E. Widmark, Q. Li, and J.-A. Gustafsson, “Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 10, pp. 4653–4657, 1992.
View at: Publisher Site | Google ScholarK. Yu, W. Bayona, and C. B. Kallen et al., “Differential activation of peroxisome proliferator-activated receptors by eicosanoids,” Journal of Biological Chemistry, vol. 270, no. 41, pp. 23975–23983, 1995.
View at: Publisher Site | Google ScholarM. V. Chakravarthy, Z. Pan, and Y. Zhu et al., ““New” hepatic fat activates PPAR to maintain glucose, lipid, and cholesterol homeostasis,” Cell Metabolism, vol. 1, no. 5, pp. 309–322, 2005.
View at: Publisher Site | Google ScholarB. M. Forman, J. Chen, and R. M. Evans, “Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors and ,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 9, pp. 4312–4317, 1997.
View at: Publisher Site | Google ScholarT. M. Willson, J. E. Cobb, and D. J. Cowan et al., “The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones,” Journal Medical Chemistry, vol. 39, pp. 665–668, 1996.
View at: Google ScholarW. R. Oliver Jr., J. L. Shenk, and M. R. Snaith et al., “A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, pp. 5306–5311, 2001.
View at: Google ScholarJ. Fu, F. Oveisi, S. Gaetani, E. Lin, and D. Piomelli, “Oleoylethanolamide, an endogenous PPAR- agonist, lowers body weight and hyperlipidemia in obese rats,” Neuropharmacology, vol. 48, no. 8 SPEC. ISS., pp. 1147–1153, 2005.
View at: Publisher Site | Google ScholarJ. Fu, S. Gaetani, and F. Oveisi et al., “Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-,” Nature, vol. 425, no. 6953, pp. 90–93, 2003.
View at: Google ScholarM. Guzmàn, V. J. Lo, J. Fu, F. Oveisi, C. Blàzquez, and D. Piomelli, “Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor α (PPAR-),” Journal of Biological Chemistry, vol. 279, no. 27, pp. 27849–27854, 2004.
View at: Google ScholarS. E. O'Sullivan, E. J. Tarling, A. J. Bennett, D. A. Kendall, and M. D. Randall, “Novel time-dependent vascular actions of Delta9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma,” Biochemical and Biophysical Research Communications, vol. 337, no. 3, pp. 824–831, 2005.
View at: Publisher Site | Google ScholarR. B. Zurier, R. G. Rossetti, J. H. Lane, J. M. Goldberg, S. A. Hunter, and S. H. Burstein et al., “Dimethylheptyl-THC-11 OIC acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure,” Arthritis and Rheumatism, vol. 41, no. 1, pp. 163–170, 1998.
View at: Publisher Site | Google ScholarJ. Liu, H. Li, S. H. Burstein, R. B. Zurier, and J. D. Chen, “Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid,” Molecular Pharmacology, vol. 63, pp. 983–992, 2003.
View at: Google ScholarF. Maingret, A. J. Patel, M. Lazdunski, and E. Honorè, “The endocannabinoid anandamide is a direct and selective blocker of the background K channel TASK-1,” EMBO Journal, vol. 20, no. 1-2, pp. 47–54, 2001.
View at: Publisher Site | Google ScholarV. Di Marzo, A. Fontana, and H. Cadas et al., “Formation and inactivation of endogenous cannabinoid anandanide in central neurons,” Nature, vol. 372, no. 6507, pp. 686–691, 1994.
View at: Google ScholarC. J. Fowler, G. Tiger, A. Ligresti, M. L. Lòpez-Rodrìguez, and V. Di Marzo, “Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis—a difficult issue to handle,” European Journal of Pharmacology, vol. 492, no. 1, pp. 1–11, 2004.
View at: Publisher Site | Google ScholarV. Di Marzo, T. Bisogno, P. L. De, D. Melck, and B. R. Martin, “Cannabimimetic fatty acid derivatives: The anandamide family and other endocannabinoids,” Current Medicinal Chemistry, vol. 6, no. 8, pp. 721–744, 1999.
View at: Google ScholarS. H. Burstein, R. G. Rossetti, B. Yagen, and R. B. Zurier, “Oxidative metabolism of anandamide,” Prostaglandins and Other Lipid Mediators, vol. 61, no. 1-2, pp. 29–41, 2000.
View at: Publisher Site | Google ScholarM. Bouaboula, S. Hilairet, J. Marchand, L. Fajas, G. Le Fur, and P. Casellas, “Anandamide induced PPAR transcriptional activation and 3T3-L1 preadipocyte differentiation,” European Journal of Pharmacology, vol. 517, no. 3, pp. 174–181, 2005.
View at: Publisher Site | Google ScholarY. Sun, S. P. H. Alexander, D. A. Kendall, and A. J. Bennett, “Cannabinoids and PPAR signalling,” Biochemical Society Transactions, vol. 34, no. 6, pp. 1095–1097, 2006.
View at: Publisher Site | Google ScholarV. J. Lo, J. Fu, and G. Astarita et al., “The nuclear receptor peroxisome proliferator-activated receptor- mediates the anti-inflammatory actions of palmitoylethanolamide,” Molecular Pharmacology, vol. 67, no. 1, pp. 15–19, 2005.
View at: Publisher Site | Google ScholarC. E. Rockwell, N. T. Snider, J. T. Thompson, J. P. Vanden Heuvel, and N. E. Kaminski, “Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor independently of cannabinoid receptors 1 and 2,” Molecular Pharmacology, vol. 70, no. 1, pp. 101–111, 2006.
View at: Publisher Site | Google ScholarS. Vandevoorde and D. M. Lambert, “Focus on the three key enzymes hydrolysing endocannabinnoids as new drug targets,” Current Pharmaceutical Design, vol. 11, no. 20, pp. 2647–2668, 2005.
View at: Publisher Site | Google ScholarN. Ueda, K. Yamanaka, and S. Yamamoto, “Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance,” Journal of Biological Chemistry, vol. 276, no. 38, pp. 35552–35557, 2001.
View at: Publisher Site | Google ScholarJ. Lengqvist, U. A. Mata De, and A.-C. Bergman et al., “Polyunsaturated fatty acids including docosahexaenoic and arachidonic acid bind to the retinoid X receptor ligand-binding domain,” Molecular and Cellular Proteomics, vol. 3, no. 7, pp. 692–703, 2004.
View at: Google ScholarD. Rueda, I. Galve-Roperh, A. Haro, and M. Guzman, “The CB1 cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase,” Molecular Pharmacology, vol. 58, no. 4, pp. 814–820, 2000.
View at: Google ScholarL. Gelman, L. Michalik, B. Desvergne, and W. Wahli, “Kinase signaling cascades that modulate peroxisome proliferator-activated receptors,” Current Opinion in Cell Biology, vol. 17, no. 2, pp. 216–222, 2005.
View at: Publisher Site | Google ScholarR. G. Pertwee, “The pharmacology of cannabinoid receptors and their ligands: an overview,” International Journal of Obesity, vol. 30, suppl. 1, pp. S13–S18, 2006.
View at: Publisher Site | Google Scholar